{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:40:44Z","timestamp":1792431644392,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.bone.2022.116598","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T02:48:57Z","timestamp":1666838937000},"page":"116598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome"],"prefix":"10.1016","volume":"166","author":[{"given":"Jeffrey","family":"Sugarman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Maruri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale J.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Tabatabai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia","family":"Cimms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Krolczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Scott","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bone.2022.116598_bb0005","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1007\/s00198-016-3702-8","article-title":"Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment","volume":"27","author":"Ovejero","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2022.116598_bb0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/pde.13273","article-title":"Epidermal nevus syndromes: new insights into whorls and swirls","volume":"35","author":"Asch","year":"2018","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.bone.2022.116598_bb0015","article-title":"Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: a case report","volume":"15","author":"Khadora","year":"2021","journal-title":"Bone Rep"},{"issue":"2","key":"10.1016\/j.bone.2022.116598_bb0020","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/ddt429","article-title":"Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia","volume":"23","author":"Lim","year":"2014","journal-title":"Hum. Mol. Genet."},{"issue":"5","key":"10.1016\/j.bone.2022.116598_bb0025","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1530\/EJE-19-0969","article-title":"DIAGNOSIS OF ENDOCRINE DISEASE: mosaic disorders of FGF23 excess: fibrous dysplasia\/McCune-albright syndrome and cutaneous skeletal hypophosphatemia syndrome","volume":"182","author":"de Castro","year":"2020","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"10.1016\/j.bone.2022.116598_bb0030","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jaad.2015.11.012","article-title":"Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy","volume":"75","author":"Lim","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.bone.2022.116598_bb0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00002.2011","article-title":"Regulation and function of the FGF23\/klotho endocrine pathways","volume":"92","author":"Martin","year":"2012","journal-title":"Physiol. Rev."},{"issue":"11","key":"10.1016\/j.bone.2022.116598_bb0040","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrendo.2009.196","article-title":"The FGF23-klotho axis: endocrine regulation of phosphate homeostasis","volume":"5","author":"Razzaque","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.bone.2022.116598_bb0045","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bone.2022.116598_bb0050","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1210\/jc.2009-1671","article-title":"Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations","volume":"95","author":"Imel","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2022.116598_bb0055","first-page":"1","article-title":"Burosumab: first global approval","author":"Lamb","year":"2018","journal-title":"Drugs"},{"issue":"21","key":"10.1016\/j.bone.2022.116598_bb0060","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab Therapy in Children with X-Linked Hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bone.2022.116598_bb0065","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"Phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research"},{"key":"10.1016\/j.bone.2022.116598_bb0070","first-page":"1","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","author":"Portale","year":"2019","journal-title":"Calcif. Tissue Int."},{"issue":"3","key":"10.1016\/j.bone.2022.116598_bb0075","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bone.2022.116598_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.866831","article-title":"A case report: first long-term treatment with burosumab in a patient with cutaneous-skeletal hypophosphatemia syndrome","volume":"13","author":"Merz","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.bone.2022.116598_bb0085","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"Jan de Beur","year":"2021","journal-title":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research"},{"issue":"2","key":"10.1016\/j.bone.2022.116598_bb0090","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S8756-3282(99)00257-4","article-title":"Normative data for iliac bone histomorphometry in growing children","volume":"26","author":"Glorieux","year":"2000","journal-title":"Bone"},{"issue":"12","key":"10.1016\/j.bone.2022.116598_bb0095","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial","volume":"34","author":"Insogna","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"10.1016\/j.bone.2022.116598_bb0100","first-page":"891","article-title":"Assessment of clinical relevant fatigue level in cancer","volume":"15","author":"Chang","year":"2007","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.bone.2022.116598_bb0105","first-page":"129","article-title":"Pain assessment: global use of the brief pain inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann. Acad. Med. Singap."},{"key":"10.1016\/j.bone.2022.116598_bb0110","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00002508-200409000-00005","article-title":"Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain","volume":"20","author":"Keller","year":"2004","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.bone.2022.116598_bb0115","series-title":"STOP, THAT and One Hundred Other Sleep Scales","first-page":"75","article-title":"Brief Fatigue Inventory","author":"Shahid","year":"2011"},{"key":"10.1016\/j.bone.2022.116598_bb0120","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2214\/ajr.146.6.1253","article-title":"Renal calcium deposition in children: sonographic demonstration of the Anderson-carr progression","volume":"146","author":"Patriquin","year":"1986","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.bone.2022.116598_bb0125","unstructured":"Labcorp, Phosphorus, 2021. https:\/\/www.labcorp.com\/tests\/001024\/phosphorus. (Accessed 8\/23\/2021."},{"key":"10.1016\/j.bone.2022.116598_bb0130","unstructured":"Labcorp, Calcitriol (1,25 di-OH Vitamin D), 2021. https:\/\/www.labcorp.com\/tests\/081091\/calcitriol-1-25-di-oh-vitamin-d. (Accessed 8\/23\/2021."},{"issue":"5","key":"10.1016\/j.bone.2022.116598_bb0135","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5414\/CN108407","article-title":"FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysis","volume":"82","author":"Lima","year":"2014","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.bone.2022.116598_bb0140","first-page":"603","article-title":"Familial Hypophosphatemia and Related Disorders","author":"Holm","year":"2003"},{"issue":"4","key":"10.1016\/j.bone.2022.116598_bb0145","article-title":"Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the medical outcomes study","volume":"33","author":"Ware","year":"1995","journal-title":"Med. Care"},{"key":"10.1016\/j.bone.2022.116598_bb0150","unstructured":"Labcorp, Vitamin D, 25-Hydroxy, 2021. https:\/\/www.labcorp.com\/tests\/081950\/vitamin-d-25-hydroxy. (Accessed 8\/23\/2021."},{"key":"10.1016\/j.bone.2022.116598_bb0155","unstructured":"Labcorp, Alkaline Phosphatase, 2021. https:\/\/www.labcorp.com\/tests\/001107\/alkaline-phosphatase. (Accessed 8\/23\/2021."},{"issue":"49","key":"10.1016\/j.bone.2022.116598_bb0160","article-title":"Reference values for the 6-minute walk test in healthy children and adolescents in Switzerland","volume":"13","author":"Ulrich","year":"2013","journal-title":"BMC Pulmonary Medicine"},{"issue":"3\u20134","key":"10.1016\/j.bone.2022.116598_bb0165","first-page":"147","article-title":"Guide-lines to the treatment of patients with X-linked hypophosphatemic rickets","volume":"66","author":"Reusz","year":"1995","journal-title":"Acta Biomed Ateneo Parmense"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328222002757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328222002757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:03:19Z","timestamp":1757613799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328222002757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":33,"alternative-id":["S8756328222002757"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2022.116598","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2022.116598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116598"}}